Dirk Reyn

Managing Partner

2016 - Current

Bioqube ventures has one mission: bringing early-stage healthcare companies to the next level. Entrepreneurial, result driven, shoulder to shoulder. Our team jointly represents over 40 years of leadership experience in identifying and funding promising scientific opportunities, is skilled in helping businesses grow and is deeply connected across corporate, government and academic research ecosystems. We cut cost, accelerate business and bring value by linking three key components: access to capital, specialized infrastructure and expertise. Our partnership with Johnson & Johnson Innovation – JLINX, is the embodiment of our mission: a multifaceted approach that enables early-stage healthcare companies to reach their full potential in a cost effective and time efficient way. Whether you are a scientist, entrepreneur or venture capitalist, bioqube ventures will face the challenge – working apart, and together with you.

President - Voorzitter van de Raad van Bestuur

2018

The FlandersBio network brings together > 300 companies with innovative, R&D-driven activities in the life sciences – companies that are for example developing biopharmaceuticals, medical technologies or agricultural or industrial biotech products. Our network welcomes companies with production activities based in Flanders as well as academic research institutes and providers of capital, services and technologies to the life sciences community. FlandersBio's strategic goals are: Achieve sustainable economic growth Stimulate knowledge transfer Create a supportive regional environment Ensure a sufficient talent pool Increase public awareness

Chairman

2013

Progress pharma is a European development/biotech company that was created in June 2013 around a multi-functional and experienced team of former Movetis/Shire-Movetis senior managers. The company is located in Belgium, at the center of a very creative and dynamic biotech scene. Progress Pharma adopts a novel business model for asset-centric drug development. We turn the asset into a venture, whose mission is to advance the asset to the next phase - or further. We create a new company around this asset, along with the asset’s originator and specialized investment funds. Each party holds a participation in the venture, reflecting its contribution and its share in the development risk. Progress Pharma conducts the due diligence, develops the development and business plans, brings the co-investors to the table and runs the project in a cost-efficient manner. When the next development phase for the asset is attained, Progress Pharma paves the way for the next future of the venture – whether it is a new investment round, IPO, a trade sale or licensing … Our deepest expertise is in Gastroenterology, dermatology and immunology. We also have experience in diabetes, pain and women’s health, Progress Pharma has worked recently on a later stage asset in GI and is now working on an innovative phase I/II immunotherapy under its management.

Chairman of Board

2018 - 2020

Across Health is a trusted advisor to senior leaders of innovative multinational healthcare organizations. With a focus on customer engagement in the digital age, we partner with our clients to design, develop, execute and measure evidence-based, omnichannel customer engagement strategies and company wide digital transformation and disruption programmes – for the short, medium and long term.

Co-founder and Board member

2018 - 2020

Spectricity is a spin-off of IMEC, a leading R&D center in nanoelectronics and digital technologies in Belgium. Spectricity develops low-cost, miniaturized, integrated spectral sensing solutions in the visible and near-infrared spectral range. Typical application areas are agriculture, food analysis, health, and biomedical applications for industrial and consumer markets.

Past President Rotary Turnhout

2017 - 2018

CEO

2016 - 2017

eTheRNA’ s mission is to help patients to fight cancer and selected infectious diseases by developing immunotherapies that target the pivotal role of dendritic cells in the human immune system. Compared to other immunotherapies, eTheRNA’s proprietary mRNA TriMix technology boosts the patient’s dendritic cells in a most comprehensive, sustainable and safe way. In three consecutive steps, TriMix stimulates dendritic cells (a) to mature, (b) to present specific antigens and (c), to induce and boost an immune response against tumor or infectious specific antigens. eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the mRNA-based TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy, headed by Prof. Kris Thielemans in tandem with Prof B. Neyns from the Brussels university hospital ‘UZ Brussel’. In 2014, eTheRNA entered into a partnership with Progress Pharma under the leadership of Dirk Reyn, former CEO of Movetis. He now heads eTheRNA’ s management team which includes: Prof. Kris Thielemans (Chief Scientific Officer), Sonja Van Meirvenne (Quality Assurance & Regulatory Affairs Lead), Carlo Heirman (Production Development Lead), Luc Lammens (Finance Lead), Dirk Van Broekhoven (General Counsel and Operations Lead) and Marina Cools (Clinical Lead). In July 2014, eTheRNA obtained from the VUB a worldwide exclusive license on the TriMix technology. In addition to EUR 12 million of non-dilutive funding, eTheRNA secured EUR 24 million in a Series A investment in March 2016 with a strong international syndicate of investors. This enables the company to continue the development of mRNA-based immunotherapies for advanced melanoma, triple negative breast cancer and infectious diseases.

Boardmember

2015 - 2016

Two years ago a group of entrepreneurial people learned to know each other on a trip to Silicon Valley: the swarms of young technology companies that completely disrupt large multinational companies or even entire industries. By being there was the entrepreneurial virus for all of them. Inspired by these risk-takers and doers, they decided on the last night to not only think this time but also to do so. Once in Belgium, they created their own start-up: uest (how ist 'in the West Flanders) to launch embracelet - a multifunctional and independant watch that allows for instance elderly people to always be close to the ones they love see www.embracelet.be

Boardmember

2011 - 2016

Non-executive member and chairman of Remuneration committee TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product. The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis. The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS).

Shareholder and executive coach

2011 - 2016

BbyB means being surprised by the haute couture of Belgian chocolate. More than twenty new flavour sensations whisk you away on a voyage of discovery. From intense to playful and smooth; but always exceptional. BbyB is about enjoying chocolate and confectionary elegance, prepared by master two star Michelin chef Bart Desmidt and chocolatier Jan Verleye.